1. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc . 2008;83:1373-1381.
2. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis . 2018;71(3 suppl 1):A7.
3. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis . 2014;64:510-533.
4. Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium . Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet . 2012;380:1662-1673.
5. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes . 1990;39:1116-1124.
6. American Diabetes Association. Standards of Medical Care in Diabetes—2018. Diabetes Care . 2018;41(suppl 1):S1-S159. Accessed January 5, 2021. https://care.diabetesjournals.org/content/41/Supplement_1
7. National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150. Accessed January 5, 2021. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
8. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA . 2016;316:602-610.
9. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA . 2011;305:2532-2539.
10. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care . 2014;37:24-30.
11. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis . 2014;63(2 suppl 2):S3-S21.
12. Mottl AK, Tuttle KR. Diabetic kidney disease: Pathogenesis and epidemiology. UpToDate. Updated August 19, 2019. Accessed January 5, 2021. www.uptodate.com/contents/diabetic-kidney-disease-pathogenesis-and-epidemiology
13. Bakris GL. Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus. UpToDate. Updated November 3, 2020. Accessed January 5, 2021. https://www.uptodate.com/contents/moderately-increased-albuminuria-microalbuminuria-in-type-2-diabetes-mellitus
14. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc . 2017;6:e005428.
15. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis . 2017;69(3 suppl 1):A7-A8.
16. Nilsson E, Gasparini A, Ärnlöv J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol . 2017;245:277-284.
17. de Boer IH, Gao X, Cleary PA, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: The DCCT/EDIC study. Clin J Am Soc Nephrol . 2016;11:1969-1977.
18. Sumida K, Molnar MZ, Potukuchi PK, et al. Changes in albuminuria and subsequent risk of incident kidney disease. Clin J Am Soc Nephrol . 2017;12:1941-1949.
19. Borch-Johnsen K, Wenzel H, Viberti GC, et al. Is screening and intervention for microalbuminuria worthwhile in patient with insulin dependent diabetes? BMJ . 1993;306:1722-1725.
20. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis . 2007;49(2 suppl 2):S12-154.
21. Bakris GL. Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus. UpToDate. Updated December 3, 2019. Accessed January 5, 2021. https://www.uptodate.com/contents/moderately-increased-albuminuria-microalbuminuria-in-type-1-diabetes-mellitus
22. Delanaye P, Glassock RJ, Pottel H, et al. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin Biochem Rev . 2016;37:17-26.
23. Levey AS, Stevens LA, Schmid CH, et al; for the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) , A new equation to estimate glomerular filtration rate. Ann Intern Med . 2009;150:604-612.
24. Wrone EM, Carnethon MR, Palaniappan L, et al; Third National Health and Nutrition Examination Survey . Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis . 2003;41:580-587.
25. Knight EL, Stampfer MJ, Hankinson SE, et al. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med . 2003;138:460-467.
26. Bernstein AM, Sun Q, Hu FB, et al. Major dietary protein sources and risk of coronary heart disease in women. Circulation . 2010;122:876-883.
27. de Boer, IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care . 2017;40:1273-1284.
28. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol . 2018;71:e127-e248.
29. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med . 2001;345:861-869.
30. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med . 1993;329:1456-1462.
31. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet . 2000;355;253-259.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med . 2001;345:851-860.
33. Fried LF, Emanuele N, Zhang JH, et al; VA NEPHRON-D Investigators . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med . 2013;369:1892-1903.
34. Bakris GL, Agarwal R, Chan JC, et al; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group . Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA . 2015;314:884-894.
35. Filippatos G, Anker SD, Böhm M, et al. Randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J . 2016;37:2105-2114.
36. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med . 2008;358:2560-2572.
37. Ismail-Beigi F, Craven T, Banerji MA, et al; ACCORD trial group . Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet . 2010;376:419-430.
38. Zoungas S, Chalmers J, Neal B, et al; ADVANCE-ON Collaborative Group . Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med . 2014;371:1392-1406.
39. Zoungas S, Arima H, Gerstein HC, et al; Collaborators on Trials of Lowering Glucose (CONTROL) group . Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol . 2017;5:431-437.
40. Miller ME, Bonds DE, Gerstein HC, et al; ACCORD Investigators . The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ . 2010;340;b5444.
41. Papademetriou V, Lovato L, Doumas M, et al; ACCORD Study Group . Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int . 2015;87:649-659.
42. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis . 2012;60:850-886.
43. Imam TH. Changes in metformin use in chronic kidney disease. Clin Kidney J . 2017;10:301-304.
44. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med . 2016;375:323-334.
45. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377:644-657.
46. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2016;375:311-322.
47. Mann JFE, Ørsted DD, Brown-Frandsen K, et al; LEADER Steering Committee and Investigators . Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med . 2017;377:839-848.
48. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med . 2016;375:1834-1844.
49. Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int . 2014;85:1303-1309.
50. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation . 2019;139:e1082-e1143.
51. National Kidney Foundation KDOQI. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl . 2012;2:279-335. Accessed January 5, 2021. www.sciencedirect.com/journal/kidney-international-supplements/vol/2/issue/4
52. National Kidney Foundation KDOQI. Evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). 2010. Accessed January 5, 2021. www.kidney.org/sites/default/files/02-10-390B_LBA_KDOQI_BoneGuide.pdf
53. Smart MA, Dieberg G, Ladhani M, et al. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev . 2014;(6):CD007333.